Biological Standardization of D. Glomerata, L. Perenne, S. Cereale and O. Europaea Pollen Extracts
NCT01567319 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 177
Last updated 2017-05-01
Summary
Allergen extracts are complex mixtures of proteins and contain varying amounts of allergenic and non-allergenic components. Many factors such as the biovariability, differences in extraction process and subsequent handling of allergens can affect the final composition, potency, and stability of allergen preparations. Genetic diversity of affected people adds another level of complexity. In order to control variability and to achieve consistency and reproducibility for optimal safety and sensitivity/specificity, it is essential to standardize the amount of allergen used in prick tests. Therefore, the system for biological standardization mainly used in Europe still is the biological calibration of in-House Reference Preparations (IHRP). The method has been adopted by the Nordic Council on Medicines as the Nordic Biological Unit, Histamine Equivalent Potency (HEP) or Skin Prick Test (SPT) value. The aim of this procedure is to estimate the biological activity of allergen extracts. The activity of an allergen extract is defined as 1 SPT per ml, when the extract provokes a specific skin reaction with a wheal of the same size as a wheal provoked by reference histamine at a concentration of 10 mg/ml, when both solutions are administrated using the same technique (prick testing) on at least 20 individuals who are sensitized to the allergen concerned.
The present study aims to standardize the allergen extracts of Dactylis glomerata, Lolium perenne, Secale cereale y Olea europaea by using this method.
Conditions
- Sensitization to Allergens
Interventions
- BIOLOGICAL
-
Skin Prick Test
Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
- BIOLOGICAL
-
Skin Prick Test - Atopic Subjects
Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
- BIOLOGICAL
-
Skin Prick Test - No Atopic Subjects
Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
Sponsors & Collaborators
-
Roxall Medicina España S.A
lead INDUSTRY
Principal Investigators
-
Arantza Vega, MD · Hospital Universitario de Guadalajara
-
Pilar Alba, MD · Hospital de Manises
-
José Manuel Zubeldia, MD · Hospital Universitario Gregorio Marañón
-
María Ángeles Gonzalo Garijo, MD · Hospital Universitario Infanta Cristina
-
Carlos Colás, MD · Hospital Clínico Universitario Lozano Blesa
-
Blanca Saenz de San Pedro · Complejo Hospitalario de Jaén
-
Lourdes Fernández, MD · Hospital Universitario Reina Sofía
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-02-29
- Primary Completion
- 2012-11-30
- Completion
- 2012-11-30
Countries
- Spain
Study Locations
More Related Trials
-
Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract
NCT01821716 ·Status: COMPLETED ·Phase: PHASE2
-
Phleum Pratense and Dactylis Glomerata Allergen Extracts Standardization
NCT06957496 ·Status: COMPLETED ·Phase: NA
-
Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen
NCT00831025 ·Status: COMPLETED ·Phase: PHASE3
-
Biological Standarization of Cupressus Arizonica Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP)
NCT02512653 ·Status: COMPLETED ·Phase: PHASE2
-
Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP).
NCT00917488 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of a Depigmented Extract of Phleum in Local Allergic Rhinitis
NCT02126111 ·Status: COMPLETED ·Phase: PHASE2
-
Biological Standardization of Blomia Tropicalis Allergen Extract
NCT01597752 ·Status: COMPLETED ·Phase: PHASE2
-
Biological Standardization of Poa Pratensis Allergen Extract
NCT01430117 ·Status: COMPLETED ·Phase: PHASE2
-
Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units
NCT00718744 ·Status: COMPLETED ·Phase: PHASE2
-
Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen
NCT00916422 ·Status: COMPLETED ·Phase: PHASE3
-
Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense
NCT00501527 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study With Allergen Extracts of House Dust Mites for Specific Sublingual Immunotherapy
NCT01014325 ·Status: UNKNOWN ·Phase: PHASE3
-
To Determine the Minimum Amount of Alternaria Alternata Allergen Extract Producing a Positive Skin Reaction.
NCT01984528 ·Status: COMPLETED ·Phase: PHASE2
-
Biological Standardization of Platanus Acerifolia Allergen Extract
NCT01739322 ·Status: COMPLETED ·Phase: PHASE2
-
Immunotherapy With Depigmented and Polymerized Allergen Extract of Olea Europaea (GPIT)
NCT00537342 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen
NCT01012531 ·Status: COMPLETED ·Phase: PHASE3
-
To Determine the Minimum Amount of Artemisia Vulgaris Allergen Extract Producing a Positive Skin Reaction.
NCT01984541 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Efficacy and Safety of Specific Immunotherapy With Modified Allergen Extracts of House Dust Mites
NCT01013116 ·Status: UNKNOWN ·Phase: PHASE3
-
Quercus Ilex and Quercus Robur Allergen Extracts Standardisation
NCT05532566 ·Status: RECRUITING ·Phase: NA
-
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
NCT01241214 ·Status: COMPLETED ·Phase: PHASE2
-
A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts
NCT01012752 ·Status: UNKNOWN ·Phase: PHASE3
-
CysLT1-r Expression Following Allergen Exposure in Asthma and Allergic Rhinitis
NCT00631254 ·Status: UNKNOWN ·Phase: NA
-
Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica
NCT00916760 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma
NCT00671268 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms
NCT00460538 ·Status: COMPLETED ·Phase: PHASE4